These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 31330498

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, Pitteloud N, Lamine F.
    BMC Endocr Disord; 2019 Dec 23; 19(1):144. PubMed ID: 31870373
    [Abstract] [Full Text] [Related]

  • 3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Dec 23; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 4. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Dec 23; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 5. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 6. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 01; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 7. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Nov 01; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 8. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 9. Type 1 diabetes induced by immune checkpoint inhibitors.
    Zhang R, Cai XL, Liu L, Han XY, Ji LN.
    Chin Med J (Engl); 2020 Nov 05; 133(21):2595-2598. PubMed ID: 32842016
    [Abstract] [Full Text] [Related]

  • 10. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.
    JAMA Oncol; 2018 Dec 01; 4(12):1721-1728. PubMed ID: 30242316
    [Abstract] [Full Text] [Related]

  • 11. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr 01; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

  • 12. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL, Wang DY, Hu JX, Tian RY, Wang W, Su Q, Li H, Wang YL.
    Ocul Immunol Inflamm; 2022 Aug 01; 30(6):1449-1459. PubMed ID: 33970759
    [Abstract] [Full Text] [Related]

  • 13. Pembrolizumab-induced type 1 diabetes.
    Maia A, Soares DM, Azevedo S, Pereira T, Amaral C.
    J Oncol Pharm Pract; 2024 Sep 01; 30(6):1118-1121. PubMed ID: 38766907
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM.
    JAMA Oncol; 2018 Feb 01; 4(2):173-182. PubMed ID: 28973656
    [Abstract] [Full Text] [Related]

  • 17. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report.
    Lopes AR, Russo A, Li AY, McCusker MG, Kroopnick JM, Scilla K, Mehra R, Rolfo C.
    Transl Lung Cancer Res; 2020 Oct 01; 9(5):2149-2156. PubMed ID: 33209634
    [Abstract] [Full Text] [Related]

  • 18. Atezolizumab induced new-onset type 1 diabetes mellitus.
    de Carlos J, Zabalza L, Garcia J, Marti M, Ayarza-Marien X, Yoldi J.
    J Oncol Pharm Pract; 2023 Jul 01; 29(5):1268-1270. PubMed ID: 36635950
    [Abstract] [Full Text] [Related]

  • 19. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
    Cho YK, Jung CH.
    Diabetes Metab J; 2023 Nov 01; 47(6):757-766. PubMed ID: 37482654
    [Abstract] [Full Text] [Related]

  • 20. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, Varricchi G, Fallahi P, Antonelli A.
    Best Pract Res Clin Endocrinol Metab; 2020 Jan 01; 34(1):101370. PubMed ID: 31983543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.